One of the Shire drugs that Takeda spotlighted in its $62 billion takeover is getting a speedy look at the FDA.
The FDA has cleared a new topical drug for actinic keratosis, a kind of precancer lesion that forms on skin due to chronic exposure to ultraviolet rays.
The ax has fallen on Takeda’s home business in Japan as part of a companywide restructuring triggered by its $59 billion Shire acquisition.
Following up on their landmark 2016 study, researchers at NYU Grossman School of Medicine found that a one-time, single-dose treatment of psilocybin, a compound found in psychedelic mushrooms, combined with psychotherapy appears to be associated with significant improvements in emotional and existential distress in cancer patients. These effects persisted nearly five years after the drug was administered
Biopharma companies have spent hundreds of billions of dollars on M&A over the last decade in moves that reshaped the drug industry and together led to thousands of layoffs, manufacturing and lab shutdowns, abandoned R&D programs, and, for some, enormous levels of debt.
As Takeda’s Shire buyout rumbles on, yet another R&D exec has found a new home. Brigitte Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.
As Japanese pharma Takeda keeps divesting assets, its new big biotech buy Shire keeps divesting research executives
Germany’s Stada (STAGn.D) on Tuesday agreed to purchase over-the-counter and prescription drugs units from Japan’s largest drugmaker Takeda (4502.T) for $660 million, part of two deals that boost its Russian and Eastern European footprint.
After getting off a $75 million IPO last year, AstraZeneca’s antibiotics spinout Entasis has hired a former Shire executive to lead its R&D programs.
Worries about competition to Shire's bread-and-butter hemophilia franchise were clear even before Takeda bought it. That fear has become reality.